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PEMODELAN DAN SINTESIS TERBITAN VANILIN YANG 
MENSASARKAN VIRUS INFLUENZA NEURAMINIDASE 
ABSTRAK 
Influenza tetap menjadi ancaman global yang serius. Ketika ini perencat 
neuraminidase (NA) iaitu zanamivir dan oseltamivir menjadi rintang kepada virus 
influenza. Oleh itu, perencat NA yang mempunyai perancah baru dan berkesan mesti 
dihasilkan. Melalui kajian ini, pendekatan pemodelan farmakofor digunakan untuk 
mencari perencat NA yang baru. Dua perisian komputer iaitu Discovery Studio 2.5 
dan LigandScout 3.01 telah digunakan. Melalui perisian tersebut, pendekatan 
farmakofor ligan dan struktur telah dijana. Pendekatan farmakofor ligan dan struktur 
akan melengkapi antara satu sama lain. Pendekatan pemodelan farmakofor ligan 
adalah berdasarkan kepada kumpulan berfungsi sama ciri. Pendekatan ini 
menggunakan set latihan iaitu suatu set sebatian kimia atau ubat-ubatan yang telah 
terkenal digunakan sebagai perencat NA. Satu lagi pendekatan yang digunakan 
adalah pemodelan farmakofor struktur, LigandScout 3.01, melalui pendekatan ini 
interaksi antara perencat NA di dalam tapak aktif dapat digambarkan. Dalam kajian 
ini, 2HU0 (dari pdb) digunakan sebagai protin sasaran yang digabungkan bersama 
oseltamivir karboksilat. Sebatian yang menunjukkan skor penjajaran yang lebih besar 
atau hampir menyamai oseltamivir karboksilat akan berpotensi meningkatkan aktiviti 
perencatan NA. Hasilnya, kedua-dua pendekatan pemodelan farmakofor ini boleh 
meramalkan aktiviti perencat NA yang berpotensi. Sebatian yang berjaya melepasi 
langkah ini akan dinilai seterusnya untuk penilaian biologikal melalui asei 
MUNANA (aktiviti perencatan NA). Dari tiga ribu sebatian yang diimbas, lebih 
kurang empat puluh tujuh sebatian yang berpotensi sebagai perencat NA telah 
dikenalpasti. Beberapa sebatian daripada empat puluh tujuh sebatian tersebut seperti 
 xiv 
 
betalain menunjukkan nilai kemuatan yang sangat baik menandakan ia berpotensi 
sebagai perencat NA tetapi sebatian-sebatian ini didapati tidak stabil (terurai) semasa 
proses pengekstrakan dan pemisahan. Sebatian yang mempunyai nilai kemuatan 
yang baik yang mempunyai kumpulan berfungsi hidroksil telah dikenalpasti dan 
dipilih. Sebatian yang mempunyai kumpulan hidroksil akan memeta samada melalui 
penerima ikatan hydrogen (HBA) atau penderma ikatan hydrogen (HBD). Ini akan 
membantu meningkatkan aktiviti perencatan NA oleh sebatian tersebut. Oleh yang 
demikian, sebatian yang mempunyai satu kumpulan hidroksil dan metoksi dijangka 
akan meningkatkan keupayaan pemetaan farmakofor yang melibatkan kedua-dua ciri 
HBA dan HBD. Oleh sebab itu sebataian benzena yang mempunyai satu kumpulan 
hidroksil dan metoksi dipilih. Perancah gelang benzena memberikan kelebihan 
seperti ketidakiralan, sintesis yang lebih ekonomik dan meningkatkan lipofilisiti 
berbanding dengan gelang dihidropiran. Penyaringan selanjutnya menemukan tiga 
puluh tiga sebatian perancah gelang benzena yang mempunyai kumpulan hidroksil 
dan metoksi. Perancah ini adalah sama dengan sebatian vanilin. Oleh yang demikian, 
pelbagai terbitan vanilin dengan kumpulan azomethin, oksazolin, pirazolin, benzena, 
sikloheksana, hidrazida dan asetat diperkenalkan melalui pendekatan separa sintetik 
bertujuan untuk meningkatkan aktiviti perencatan NA. Terbitan vanilin menunjukkan 
mod pemetaan yang baik sepertimana pemetaan farmakofor pada set latihan. 
Penjajaran dasar struktur menunjukkan perancah vanilin menunjang dalam tapak 
aktif NA seperti penjajaran pada oseltamivir karboksilat. Lima terbitan vanillin telah 
disintesis. Sintesis terbitan vanillin akan membuktikan analisis pemodelan 
farmakofor mengenalpasti potensinya sebagai perencat NA. Terbitan vanilin tersebut 
di asei menggunakan asei MUNANA. Keputusan asei menunjukkan bahawa terbitan 
vanilin menunjukkan aktiviti perencatan NA yang berkesan tetapi lebih lemah 
 xv 
 
berbanding dengan oseltamivir karboksilat iaitu satu-satunya agen perencat NA yang 
berada di pasaran. Daripada keputusan asei MUNANA, ternyata bahawa sebatian 20 
menunjukkan perencat NA yang terkuat dengan nilai IC50 0.18 µM berbanding 
terbitan vanillin yang lain-lain diikuti sebatian 18 yang menunjukkan IC50 0.36 µM 
lebih kuat daripada DANA, 17, 19 dan 21 dengan IC50 0.44, 1.61, 1.22 dan 0.76 µM. 
Daripada pemerhatian ini, adalah disimpulkan bahawa kumpulan karboksilat 
memainkan peranan yang penting bagi meningkatkan aktiviti perencatan NA seperti 
yang dilihat melalui asei MUNANA.  
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MODELLING AND SYNTHESES OF VANILLIN DERIVATIVES 
TARGETING INFLUENZA VIRUS NEURAMINIDASE 
ABSTRACT 
Influenza remains a serious global threat. To date, zanamivir and oseltamivir 
used as NA inhibitors were reported to be resistant to influenza virus. Therefore, new 
and effective NA inhibitors must be discovered. In this study, pharmacophore 
modelling approach was used to search for NA inhibitors with new scaffold. Two 
computer softwares such as Discovery Studio 2.5 and LigandScout 3.1 was utilized. 
Through the softwares, the pharmacophore modelling approaches was generated. 
Ligand-based and structure-based pharmacophore modelling approaches will 
complement each other. Ligand-based pharmacophore modelling approach is based 
on common features functional groups. This approach utilize training set, a set of 
established compounds used as NA inhibitors. The training set was selected from 
chemically diverse NA inhibitors. The other approach is structure-based 
pharmacophore modelling. Through this approach, the interactions between NA 
inhibitors in active site can be observed. In this study, 2HU0 (from pdb) was used as 
protein target incorporated oseltamivir carboxylate. Compound which shows greater 
alignment score towards oseltamivir carboxylate will potentially enhance NA 
inhibition activity. As a results, both pharmacophore modelling approaches, 
potentially NA inhibitors could be predicted. Compounds which pass through this 
step was further to be evaluated for biological evaluation ie MUNANA assay (NA 
inhibition activity). From the three thousand compounds screened, about fourty 
seven compounds potentially as NA inhibitors was identified. Some compounds 
among the fourty seven compounds such as betalain showed very good fit value 
indicating potential NA inhibitors but these compounds was found to be unstable 
 xvii 
 
(decomposed) upon extraction and isolation process. Compounds with good fit 
values bearing a benzene ring scaffold with a hydroxyl group were selected. 
Compounds bearing a hydroxyl group will map either by a hydrogen bond acceptor 
(HBA) or a hydrogen bond donor (HBD). This will proposed the enhancement of the 
compounds NA inhibition activity. Thus, it is proposed to search compounds which 
bearing a hydroxyl and a methoxy group which could enhance the pharmacophore 
mapping capacity involving both, HBA and HBD features. Therefore, benzene ring 
bearing a hydroxyl and a methoxy group are selected. The benzene ring scaffold 
gave the advantages of non-chirality, more economical synthesis and increased 
lipophilicity compared with the dihydropyran ring. Further screening found thirty 
three compounds with benzene ring scaffold bearing hydroxyl and methoxy group. 
The scaffold is similar to vanillin compound. Therefore, various vanillin derivatives 
with azomethine, oxazoline, pyrazoline, benzene, cyclohexane, hydrazide and acetate 
groups were introduced through semi-synthetic approach in order to enhance NA 
inhibition activity. The vanillin derivatives showed a good mapping mode 
corresponded to the training set pharmacophore mapping. The structure-based 
alignment showed that the vanillin scaffold anchored in the NA active site similar to 
oseltamivir carboxylate alignment. Five vanillin derivatives were synthesized. The 
syntheses of vanillin derivatives will prove the pharmacophore modelling analysis to 
identify its potential as NA inhibitors. The vanillin derivatives was assayed using 
MUNANA assay. The assay results shows that vanillin derivatives exerted 
significant NA inhibition activity but weaker compare to oseltamivir carboxylate 
which is an NA inhibitor found in the market. From the MUNANA assay results, it 
was revealed that compound 20 showed the strongest NA inhibition activity with 
IC50 value of 0.18 µM among other vanillin derivatives followed by compound 18 
 xviii 
 
which showed IC50 0.36 µM greater than DANA, 17, 19 and 21 with IC50 0.44, 1.61, 
1.22 and 0.76 µM, respectively. From this observation, it was concluded that 
carboxylate group plays an important role in enhancing NA inhibition activity as 
observed in MUNANA assay.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Influenza 
The influenza virus is a causative agent which causes high morbidity and mortality. 
The word “Influenza” comes from the Italian word “influence” used since the middle 
age to describe the disease as it was originally believed that the disease came from 
the “influence” of the stars [1]. Influenza is a respiratory viral disease infecting the 
whole respiratory tract including the nose, sinuses, throat, lungs as well as the middle 
ear [2]. The influenza virus spread through respiratory secretions during coughing 
and sneezing with direct or indirect contact. After virus replication and the spread of 
infection throughout the upper and lower respiratory airways, the virus will assemble 
in the nasopharyngeal airway for five to ten days. The incubation period is about one 
to four days before obvious symptoms such as flu-like symptoms occurred. Multi-
system complications will affect lungs, heart, brain, liver, kidney and muscle and 
consequently death due to either primary viral infection or secondary bacterial 
pneumonia [3]. 
 
Approximately 20% of children and 5% of adults have symptomatic influenza 
infection worldwide [4]. Complications from influenza illness such as pneumonia, 
cardiopulmonary or other chronic diseases lead to more than 200,000 
hospitalizations. About 30,000 to 50,000 deaths per year were reported in the United 
States of America [5]. The risk for complications is higher among the elderly above 
65 years old, young children, and those with certain underlying medical conditions. 
In fact, about 63% of all hospitalizations occur among persons aged more than 65 
2 
 
years old, of which 5-10% were fatal [6]. Hospitalization rates among children aged 
below 24 months are comparable to the rates reported among the elderly [7].  
 
 1.1.1 Influenza virus 
Influenza infections are caused by negative strand RNA viruses of the 
orthomyxoviridae family of influenza virus type A, B and C. The three different 
types of influenza, A, B and C can be distinguished by antigenic differences between 
their nucleocapsid (NP) and matrix (M) proteins. Influenza virus type A is further 
classified according to their surface glycoproteins hemagglutinin (HA) and NA [8]. 
Influenza A viruses are subdivided into subtypes, and the current nomenclature 
system includes the host of origin, geographic location of first isolation, strain 
number, and year of isolation. For example: A/Swine/Iowa/15/30 (H1N1); where, A 
refers to Influenza A, Swine - the host of origin, Iowa - the geographic location of 
the first isolates, 15 - strain number and 30 is year of isolation, i.e. 1930. By 
convention, if the host of origin is human, then it is not included in the nomenclature 
such as A/Puerto Rico/8/34 (H1N1) [9].  
 
There are sixteen known HA subtypes (H1-H16) and nine known NA subtypes (N1-
N9) which give rise to many possible different influenza A subtypes. The subtypes of 
influenza A, such as H1N1 (1918 pandemic), H2N2 (1957 pandemic) and H3N2 
(1968 pandemic) viruses have caused illnesses to people globally in the twentieth 
century [10]. Three prominent subtypes; H5, H7 and H9 are known to infect both 
birds and humans. Influenza A viruses are also classified into strains such as low and 
highly pathogenic on the basis of genetic features and the severity of the illness they 
can cause. Low pathogenic avian influenza (LPAI) are viruses which usually 
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associated with mild disease whereas highly pathogenic avian influenza (HPAI) 
viruses are associated with severe illness and high mortality in poultry [11]. All the 
three influenza viruses, A, B and C infect humans. However, they have different 
epidemiologic characteristics. Influenza A viruses caused the flu pandemic which 
could infect birds, mammals and humans. Wild birds are known to be the natural 
host of these viruses. Influenza B virus are known to infect humans and seals while 
influenza C virus are known to infect only humans and pigs [12].  
 
1.1.2 Structure of influenza virus 
Influenza virus shows pleomorphic morphology with an average diameter of 120 nm. 
Figure 1.1 shows the virus surface glycoprotein membrane spikes which consist of 
about 500 HA and NA per virus, emerging from the lipid bilayer envelope. For 
influenza virus A and B, nucleocapsid proteins (NP) of matrix protein M1 contain 
eight viral RNA (vRNA) segments of different sizes. Each of them is associated with 
a polymerase complex comprised of polymerase B2 (PB2), polymerase B1 (PB1), 
and polymerase A (PA) proteins [12]. In viral polymerase complex, PB1 has the 
polymerase and endonuclease activities [13], PB2 binds to the methylated cap of host 
cell mRNA [10] and PA is essential for vRNA synthesis as well as for proteolytic 
activity [12]. 
 
The association of these four proteins namely NP, PB1, PB2, and PA as a whole 
represents the genetic transcription and is known as the viral ribonucleoprotein 
complex (vRNP) [14]. It is surrounded by the matrix protein (M1) which forms a 
layer underneath the lipid cell-derived envelope, providing rigidity to it and plays a 
key role in virus progeny assembly and budding process [15]. The M1 protein also 
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takes part in transporting the vRNP complex from the nucleus in combination with 
the Non-structural protein, NS2 or nuclear export protein (NEP), which is also 
present within the virus [16].  
 
The eight gene segments of influenza A and B viral genome encode for ten proteins, 
nine of which are incorporated in the progeny virions. Six segments of the genome, 
PB2, PB1, PA, HA, NP and NA encode for one viral protein. Two open reading 
frames (ORFs) in segments 7 and 8 encode for M1 and M2 proteins and NS1 and 
NS2 proteins, respectively [17]. 
 
 
Figure 1.1 The cross section of influenza virus 
showing the structure of NA which 
plays a key role in the viral 
infections, adapted from Sidorenko 
& Reichl [12]. 
 
1.1.3 Life Cycle of the influenza virus 
Figure 1.2 illustrates the life cycle of influenza virus and the involvement of NA and 
HA in the host cell involving multi-steps process. In the first stage, the virus will 
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fused the host cell through attachment of HA to Sialic acid (SA) on the cells surface 
of the host respiratory tract system. The host cell engulfs the virus and endocytosis 
process takes place. As the virus invades the host cell, acidic conditions takes place 
in the endosome resulting in HA fusing with the host cell vacuole's membrane. The 
ion channel (M2) opens and allows protons to rush in through the viral envelope and 
acidify the virus core. This situation promotes the core to dissemble and release the 
viral RNA and core proteins.  
 
 
Figure 1.2 Replication cycle of influenza A virus showing 
binding and  entry of the virus, fusion with 
endosomal membrane and release of viral RNA, 
replication within the nucleus, synthesis of 
structural and envelope proteins, budding and 
release of virus progeny capable of infecting 
neighbouring epithelial cells, adapted from Cox & 
Kawaoka [18]. 
 
Next, the core proteins and vRNA form a complex which was transported into the 
cell nucleus where the RNA-dependent RNA polymerase initiates the transcription 
process. The vRNA is then transferred into the cytoplasm or translated or remained 
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in the nucleus. The Golgi apparatus then secretes the newly synthesized viral proteins 
or transports it back into the nucleus to bind with vRNA and finally forms new viral 
genome materials and assembles them into a viral progeny.  
 
HA and NA found on the host cell’s surface glycoproteins were clustered into a 
bulge in the cell membrane. After leaving the nucleus, the vRNA and viral core 
proteins enter the cell membrane of the new viral progeny. The viral progeny 
becomes mature virus and emerges from the cell in a spherical shape from the host 
membrane, bearing HA and NA. In the last stage, the virus fused to the cell through 
HA and the mature virus is released once NA cleaves SA which is attached to HA 
[19]. 
 
1.2 Pandemic influenza  
An influenza pandemic spreads the deadly disease rapidly around the world and 
transmits new influenza viral strain from animal species such as pigs, chicken and 
ducks to human as well as from human to human. Every year, many people are 
facing the risk due to the spreading of new virus strain. The first recorded influenza 
pandemic was an outbreak in 1580, which began in Asia and spread to Africa, and 
then to Europe along two corridors from Asia Minor and North-West Africa [20]. In 
the same year, the whole of Europe was infected from North to South over a six 
month period, and the infection subsequently spread to America. The illness rates 
were high which caused approximately 8,000 deaths reportedly from Rome and some 
Spanish cities [21].  
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The pandemics of 1830-1833 and 1918-1920 caused severe fatality cases [22]. The 
pandemic began in 1830 in China, from where it spread southwards to reach the 
Philippines, India and Indonesia, and across Russia into Europe. The contagion 
spread into North America to cause outbreaks in 1831-1832, recurred in Europe at 
the same time and recurred again in Europe in 1832-1833 [23]. The influenza 
pandemic was known to occur about three times in a century. The most deadly 
outbreak was the 1918 flu pandemic of type A influenza H1N1. The death toll was 
estimated to be approximately within 20 to 100 million people. The H2N2 1957 
Asian (replacement of H1N1 subtype) and the H3N2 1968 Hong Kong (replacement 
of H2N2) pandemics were also associated with high death tolls [24]. The pandemics 
timeline is shown in Figure 1.3.  
 
 
Figure 1.3  Sequence of antigenic shifts in the twentieth century, 
adapted from David et al., [25]. 
 
Figure 1.3 shows the influenza pandemics since 1918 until the emergence of HPAI 
A/H5N1 in 2006 [26]. The origin of the H1N1 1918 pandemic strain was associated 
with avian species, while H2N2 1957 and H3N2 1968 pandemics were due to 
combination of viruses with HA, NA and PB1 genes from avian influenza A viruses 
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[27]. This great pandemic death toll was due to an extremely high infection rate of 
more than 50% and the extreme severity of the symptoms caused by cytokine storms 
[28]. Figure 1.4 illustrates the involvement of animal species in the pandemic found 
in avian and human species caused by the combination of HA and NA subtypes. 
  
The influenza virus that caused the 1918-1919 pandemic was observed to make a 
consistency pattern that persists up to date according to scientists from the National 
Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, 
USA [25]. The viruses continue to circulate for nine decades and any antigenic shift 
with genetics reassortment can result in novel and highly pathogenic strains of 
human influenza. New influenza viruses will constantly emerge by mutation. This 
new variant then replaces the older strains as it rapidly spreads to the human 
population [29].   
 
 
Figure 1.4    Circulation of Influenza A viruses in humans. Of the 144 
total combinatorial possibilities, only three HAs and two 
NAs, in only 3 combinations (H1N1, H2N2, and H3N2), 
have ever been found in truly human-adapted viruses, 
adapted from David et al., [25]. 
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As the two of the eight genes i.e. HA and NA promote sixteen and nine subtypes 
respectively, thus, there are about 144 possible HA-NA combinations. However, 
only three combinations, H1N1, H2N2 and H3N2 have ever been found in influenza 
viruses which can infect humans. Other combinations, such as avian influenza H5N1, 
occasionally infect human as they are bird viruses and not human viruses. The viral 
genes may assist the virus survival due to the new strength and the ability to infect 
new host. This situation was likely to initiate the 1918 pandemic. Human immune 
system was known to promote antibodies as defence factor against influenza virus 
HA and NA. Through this mechanism, the virus reacts by changing its character and 
resists the antibodies which recognize it and persists in environment until now [30]. 
 
1.3 Anti-Influenza Drug Target 
The role of influenza NA in the lifecycle of the virus and the conserved nature of 
their active site has led the enzyme to be considered as an excellent target for 
antiviral drug design [31]. The discovery of NA inhibitors programme have been 
initiated due to the essential role of NA in the virus replication and its highly 
conserved active site [32]. The crystal structure of influenza virus NA complexed 
with both N-acetylneuraminic acid [33] and 2,3-didehydro-2-deoxy-N-
acetylneuraminic acid (Neu5Ac2en or DANA) [34] proved to be useful in structure 
based rational drug design [35]. 
 
Numerous high resolution crystal structures of influenza NA and its complex with 
SA and other small molecule inhibitors have been determined [36]. Analysis of these 
structures showed some common structural features among all influenza NA: (a) NA 
active site contains well formed, large, and relatively rigid binding pockets; (b) the 
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key residues make direct contacts with the bound inhibitors are highly conserved and 
interact in a similar fashion; (c) NA active site contains a large number of polar or 
charged residues, suggesting that electrostatic interactions might play a critical role 
for any successful inhibitors [37]. The first clue as to the function of influenza virus 
NA came from experiments by Seto and Rott which showed that NA activity was 
associated with the release of virus from infected host cells [38]. 
 
1.4 Influenza Neuraminidase (NA) 
NA is a glycoprotein that can be found in many life-forms such as viruses, bacteria, 
protozoa, mycoplasma and fungus including in higher animals, birds and mammals 
[39]. In influenza A and B viruses, NA adopts a tetramer structure that spikes out 
from the surface of the virus core [40]. The NA’s structure is a box-like head on top 
of a stalk. The stalk length is considered to be one of the important factors that 
contribute to the virulence of H5N1 and H1N1 strains. The NA enables the virus to 
be released from the host cell to cause infection in human. The enzyme cleaves SA 
from the host cell receptor glycoproteins to promote influenza virus replication [41].  
 
Influenza A virus NA can be classified into two groups; Group 1 and 2 (NA1 and 
NA 2). The NA 1 group consists of subtypes N1, N4, N5 and N8 while the other 
group includes N2, N3, N6, N7 and N9 [42].  Subtypes N1 and N2 are known to 
cause epidemics in human and subtype N3 or N7 are found to cause fatality to human 
[43].  All these nine subtypes are found in avian hosts and only N1 and N2 subtypes 
are found in influenza virus strains which infect human. The most prominent 
structural feature of group NA1 is the formation of a pocket located at the 150-loop 
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[44]. Contrary to other structurally determined N1 NAs, one of the 2009 H1N1 
viruses, lacks the 150-pocket [45]. 
 
NA and HA both recognize carbohydrate structures and bind to terminal SA [46] 
units on the surface of the host cell. Binding of HA to its receptor initiates viral entry 
into the host cell. NA cleaves the α-(2,3) and α-(2,6) glycosidic linkage of terminal 
SA  and reduces the number of receptor binding sites for HA on the host cells and the 
viral progeny. This will allow the mature virus to detach from the host cell during 
release and prevent self-aggregation mediated by HA [47]. Therefore, NA plays a 
crucial role for virus spread and infection. Inhibition of this enzyme therefore, would 
provide a potential mechanism to halt the infection. 
 
1.4.1 The structure of Influenza NA 
The NA structure composes of four identical subunits forming a tetramer structure of 
about 240 kDa. The tetramer has a mushroom-like shape, where the head is 
composed of four catalytic domains and the stalk is formed by the extended N-
terminal sequences of the four subunits. The stalk amino sequence can vary in length 
and glycosylation for different subtypes [48]. In NA crystal structure, the subunits 
assemble around a four-fold axis. The typical β-sheet dominated six-blade propeller 
fold of each subunit was first observed in 1983 by Varghese et al. for N2 and is 
conserved for other subtypes (N9, N4, N6, N8, N1; Influenza B NA). In the centre of 
each subunit, conserved residues form the catalytic active site [49]. The primary NA 
structure of various species shows some 30% difference in sequence identity [50]. 
For instance, bacterial species NA has a conserved ‘ASP-box’ region which occurs 3 
to 5 times in sequence which was not seen in the virus NA. There are some common 
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features within the catalytic domain observed from the NA X-ray crystal structure 
from various viruses, bacteria and protozoa. The catalytic site was located at the 
centre of the anomer structure. The anomer catalytic domain consists of six four-
stranded antiparallel β-sheets folded into a propeller shape arrangement [51]. A 
tetramer crystal structure of NA, (PDB: 09N1) shown in Figure 1.5 as a ribbon 
representation.  
 
 
Figure 1.5   A ribbon representation of crystal structure 
of NA tetramer, adapted from Li et al., 
[45]. 
 
The tertiary structure (i.e. the anomer that is made up of a single polypeptide chain) 
is linked together by the disulfide bonds between the thiol groups of two peptidyl-
cysteine residues in the active site. The active site is located inside the individual 
anomer and they contain conserved amino acids which will be discussed in detail in 
the following sections. 
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1.4.2 The active site of influenza NA and binding mode 
Varghese et al successfully characterized the structure of N2 at a resolution of 2.9 Å 
in 1983 [52].  Four identical polypeptides of N2 subtype head was separated using 
the pronase enzyme. The tetramer protein molecules were crystallized and elucidated 
using X-ray diffraction. They identified each anomer of six four-stranded anti-
parallel β-sheet arranged around a pseudo six-fold axis. The active site is known to 
be highly conserved as shown in Figure 1.6.  
 
 
Figure 1.6   Structure of the complex between H2N2 
influenza virus NA and SA (PDB code: 
2bat). Hydrogen bonds are represented with 
green dotted lines, adapted from Kim et al., 
[53]. 
 
The residues that made up the active site include ARG371, ARG118, GLU119, 
ASP151, ARG152, ARG156, ASP198, ARG224, GLU227, ASP243, HIS274, 
GLU276, GLU277, ARG292, ASP330, LYS350 and GLU425. These amino acid 
residues were divided into three groups [42] and summarized in Table 1.1. 
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Table 1.1 The three groups of conserved amino acids of Influenza A NA active 
site. 
 
 
 
A number of high-resolution crystal structures of influenza NA and its complex with 
various small molecule inhibitors have been determined and are available from 
Brookhaven Protein Data Bank (PDB). Analysis of these structures revealed some 
common structural features. The NA active site contains some well-formed, large 
and relatively rigid pockets. All residues making direct contact with the substrate are 
strictly conserved and interact in a similar fashion with both substrate and inhibitor 
molecules and the active site contains an unusually large number of polar residues, 
suggesting that electrostatic interactions plays a key role for any inhibition activity. 
This is reasonable since NAs carbohydrate substrates are polar in nature and the 
electrostatic interactions promotes stability in the binding to NA inhibitors.  
 
The negatively charged carboxylate group of SA makes strong charge-charge 
interactions with positively charged side chains of the ARG triad (ARG118, 292 and 
371) of NA and the N-acetyl group of SA, opposite to the carboxylate group, making 
both polar and hydrophobic interactions with NA [36]. These two interactions help to 
anchor the scaffold of SA. The NA active site can be further divided into three major 
binding pockets. Pocket 1 is formed by GLU276, GLU277, ARG292 and ASN294. 
15 
 
This pocket interacts with the glycerol moiety of SA which proved to be the key to 
the binding of potent cyclohexene-based NA inhibitors [53]. There is a well-formed 
hydrophobic cavity of pocket 2 that is not utilized by SA for binding. This pocket is 
surrounded on one side by ALA246, on the other side by ILE222 and an ARG224 
side-chain forms the bottom.  
 
All the three residues are highly conserved and could provide hydrophobic 
interactions with potential inhibitors. Residues such as GLU119, ASP151, ARG152, 
TRP178, SER179, ILE222 and GLU227 of NA form Pocket 3. They interacted with 
both the C4 hydroxyl and N-acetyl groups of SA. Pocket 3 is very spacious and deep 
inside upon inhibitors binding in it which is not fully utilized by SA. Particularly, 
there are negatively charged residues such as GLU119, GLU227 and ASP151 
surrounded C4 hydroxyl group which could be explored for possible charge-charge 
interactions.  
 
1.4.3 NA inhibitors 
Currently, two FDA approved antiviral drugs such as oseltamivir and zanamivir 
(Figure 1.7) act by inhibiting influenza virus NA thereby blocking the release of 
virions progeny, consequently reducing viral infectivity [54]. 
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(a) (b) 
 
Figure 1.7   Structure of oseltamivir (a) and zanamivir (b) 
 
1.4.3.1   The discovery of zanamivir and oseltamivir 
In late 1960s, 2,3-didehydro-2-deoxy-N-acetylneuraminic acid or Neu5Ac2en 
(DANA) was shown to have weak NA inhibitory activity. Little progress was made 
until after a complex crystal structures of NA with SA and DANA were obtained in 
early 1990’s and the anti-influenza research was frequently highlighted [55]. The 
scheme of zanamivir and oseltamivir discovery shown in Figure 1.8, led to the 
discovery of oseltamivir carboxylate, the derivatives and analogue of oseltamivir 
ethyl ester. 
 
Replacing the C4-OH group of transition state compound of sialic acid with a basic 
amino (NH2) group have strengthen the binding by introducing additional 
electrostatic interactions with the negatively charged residues in NA active site [53]. 
The isopentyl side chain of oseltamivir carboxylate makes a hydrophobic interactions 
with NA active site [56]. The isopentyl group also binds to the highly polar active 
site [54]. However, experimental data show that oseltamivir carboxylate not only 
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interacts by using its hydrophobic isopentyl moiety but the interaction is absolutely 
essential to its inhibitory potency.  
 
 
 
Figure 1.8     Structural modification of SA towards the development of oseltamivir 
and zanamivir, adapted from Willard et al., [57]. 
  
 
The nature of the interaction by 3-pentyl moiety is purely hydrophobic [58]. 
Oseltamivir carboxylate has similar inhibitory potency as zanamivir without having 
to incorporate permanently positively charged guanidino moiety due to the new and 
novel interactions between NA and oseltamivir carboxylate in NA active site. 
Introducing the polar carboxylate with an ethyl ester, the prodrug molecule, 
oseltamivir phosphate has a more balanced polar and hydrophobic property and is 
readily absorbed through oral administration [57]. 
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Oseltamivir ethyl ester is the prodrug that requires ester hydrolysis to be converted to 
its active form, oseltamivir carboxylate [40]. The development of oseltamivir 
resulted from the combination of rational drug design and availability of high 
resolution X-ray crystal structures of SA and its analogues bound to influenza A and 
B NA [53]. After the identification of oseltamivir carboxylate as a potent NA 
inhibitor, modifications of the molecule was done in order to increase its oral 
bioavailability. Oseltamivir phosphate (Tamiflu, Roche) was licensed by the FDA in 
October 1999 for the treatment and prophylaxis of influenza infection [53]. 
 
The sialic acid which replaces C4-OH to guanidino group of DANA increases its 
basicity which was resulted in the formation of zanamivir as one of the most potent 
inhibitors. The highly polar nature of zanamivir makes the membrane permeability 
difficult to be delivered orally. Therefore, zanamivir is administered through nasal 
inhalation as dry powder [53].  These functional groups confers zanamivir a tight 
affinity for the active site of the viral enzyme NA [59].  
 
Although DANA was shown to have weak NA inhibitory activity previously and 
little progress was made until after a complex crystal structures of NA with SA and 
DANA were obtained but in early 1990’s, the anti-influenza research was frequently 
highlighted [55]. The discovery of zanamivir in 1989 was the outcome of Computer 
Assisted Drug Design (CADD) based on the crystal structure of the influenza NA 
active site resulting in the first potent, selective NA inhibitor [60]. Zanamivir has 
been commercially known as “Relenza” (GlaxoSmithKline) since 1999 when it was 
approved by the FDA for marketing in the United States followed by its approval in 
other seventy countries [61].  
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The crystal structure of oseltamivir carboxylate complexed with NA shown in 
Figure 1.9 indicated that cyclohexene series of inhibitors adopted similar binding 
mode as SA, i.e., the carboxylate and N-acetyl moieties of the inhibitors interact with 
NA in a similar fashion to SA. The binding interactions in the NA active site 
anchored the compound scaffold. The crystal structure also revealed that the 
isopentyl side chain of oseltamivir carboxylate made hydrophobic interactions with 
pocket 2 [62]. Interestingly, the isopentyl group also binds to the highly polar pocket 
1. Pocket 1 is typically considered a polar pocket because the presence of charged or 
polar residues and the polar interactions with a bound inhibitor’s glycerol moiety are 
essential toward inhibitory activity [63].  
 
 
Figure 1.9 Complex structures of NA-zanamivir (A) and NA-oseltamivir 
carboxylate (B). Red dashes indicate polar interaction and black 
dashes indicate hydrophobic contacts, adapted from Chun et al., [64]. 
 
 
However, experimental data show that oseltamivir carboxylate not only interacts 
directly with this pocket using its hydrophobic isopentyl moiety but the interaction is 
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absolutely essential to its inhibitory potency. The nature of this interaction is purely 
hydrophobic [65]. Oseltamivir carboxylate has similar inhibitory potency as 
zanamivir without having to incorporate permanently positively charged guanidino 
moiety due to the new and novel interactions between NA and oseltamivir 
carboxylate in pockets 1 and 2. Introducing the polar carboxylate with an ethyl ester, 
the prodrug molecule oseltamivir ethyl ester has a more balanced polar and 
hydrophobic property and is readily absorbed through oral administration [57].  
 
1.5 Binding of oseltamivir and zanamivir to H1N1 NA active site 
The predicted binding constant for oseltamivir is at least 10 times higher than that for 
SA in H1N1 NA active site. Figure 1.10 showed the NA active site of H1N1.   
 
 
Figure 1.10   A model of NA active site using AutoDock 
showing the two regions of the H1N1 NA 
binding site. The red region (A) is the 
electronegative region, where the amine-
rich functional groups of ligands bind, and 
the large blue region (B) a large 
electropositive zone, adapted from Lin et 
al., [66].  
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The hydrogen bond-rich interaction of SA has not resulted in higher binding affinity. 
The higher affinity of oseltamivir is probably related to interaction between the 
amine-rich terminus of the ligand and glutamic acid in the binding site. In their 
report, zanamivir had a binding affinity similar to that of sialic acid, with docking 
energy of -12.84 kcal/mol and -12.47 kcal/mol, respectively [67]. Zanamivir also has 
seven possible hydrogen bonds at the binding site. The significantly higher binding 
affinity of oseltamivir (-13.94 kcal/mol) as compared with zanamivir, even though 
both have a similar number of hydrogen bonds indicated that there may be a 
structural parameter that impacts binding that was not determined in previous studies 
[68]. 
 
1.6 Exploitation of the 150 Cavity in NA active site 
All of the nine known NA subtypes from influenza A virus can be divided into two 
groups on the basis of phylogenetic analysis: Group 1, consisting of N1, N4, N5, and 
N8 subtypes, and Group 2, consisting of N2, N3, N6, N7, and N9 subtypes [69]. X-
ray crystallography of several NAs revealed that the active sites of Groups 1 and 2 
differ markedly: In Group 1, a loop of amino acids, consisting of residues 147−152 
(150 loop), adopts an open conformation, whereas in Group 2 subtypes, this loop is 
closed [70].  The 150 cavity of NA active site was shown in Figure 1.11. 
 
The open loop conformation, a cavity near the active site (150 cavity) becomes 
accessible to other ligands of the N1, N4, N5, and N8 subtypes. The discovery of the 
150 cavity has led to the development of several inhibitors designed to exploit 
contacts in this region and increase specificity [71]. However, the recent crystal 
structure of a partially open 150 loop in a complex of N2 with oseltamivir and 
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several in silico studies have indicated that movement of the 150 loop may not be 
restricted to group 1 NAs [72]. 
 
 
Figure 1.11    The Group 1 NA active site showing 150 cavity 
adopting an open conformation, adapted from 
Thompson et al., [69]. 
 
 
1.7 Inhibitor design based on a benzoic acid scaffold 
The high potency and oral activity of oseltamivir promoted alternative scaffolds to 
replace SA. By introducing benzene ring scaffolds, the number of chiral centers 
could be minimized, potentially simplifying the chemical synthesis [73]. The 
challenge is to configure substituents on the ring to optimize the interactions with the 
active site. The residues interacts with SA are conserved in all influenza NAs, but 
some free SA showed some differences in size and shape between strains and 
sometimes differ in potency between N1, N2 and B NAs [74] (Figure 1.12). In 
addition, NA inhibitors with a hydrophobic side chain often show differences in 
potency between the two structural groups of type A NA [75]. 
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Several benzoic acid derivatives have been reported to bind to influenza B NA.  The 
X-ray crystal structures showed that benzoic acid derivatives bind to the active site in 
the same orientation as SA [76]. The derivatives with common carboxylate 
substitution at the C2 position, maintains the native interaction with ARG292, 
ARG118, and ARG371; and the N-acetyl substitution at the C5 pocket maintains the 
interaction with ARG152. The benzene ring scaffold (hydrophobic) fits into the 
glycerol binding site (C6 pocket) of the SA [77]. 
 
Figure 1.12     The NA pockets that surround the transition 
state of DANA. In benzoic acid series, 
pocket 6 is adjacent to C4 of the Benzene 
ring (PDB ID: 1NNB). Figure made with 
PDB ID: 1NNB, adapted from Finley et al., 
[77].  
 
One good example of benzoic acid derivatives which have been studied as NA 
inhibitor is Inhibitor 1 (Figure 1.13).  
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Figure 1.13   Inhibitor 1, adapted from Atigadda et al. [73]. 
 
This compound lacks the C4 pocket substituent but showed NA activity as observed 
with other compounds with a similar hydrophobic substituent on the benzene ring 
[73]. Inhibitor 1 exhibited moderately potent activity from low to mild (nM) activity 
against NAs of the N2 and N9 subtypes of influenza A virus, with less NA inhibitory 
activity against influenza B, as observed for other compounds with a similar 
hydrophobic substituent on the benzene ring [73].  
 
However, attempts to design substituents on the benzene ring that occupy both the 
negatively charged C4 pocket and the glycerol binding site (C6 pocket) of SA have 
been difficult because the two sub sites are off set from the plane of the benzene ring 
[78].  The results of molecular modeling studies suggested that a different 
arrangement of the benzene ring may be needed, and one way to alter the 
arrangement may be to change the size of the hydrophobic substituent, such that an 
increase or a decrease in steric crowding reorients the benzene ring in the binding 
site [78]. 
 
 
